PLUS THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM RESPECT™ PHASE 1 CLINICAL TRIAL IN RECURRENT GLIOBLASTOMA

Al's Comment:

 I went to the presentation on this and it was impressive. RNL is a nanoliposomal formulation that  delivered directly to where it is needed in the brain via convection enhanced delivery.  It releases radiation in a much higher dose to the tumor bed than external beam radiation does, and a smaller dose to the surrounding tissue.  It is still very early of course but the concept is elegant and early data looks good.  They reported that patients who previously used Avastin did not do as well as those who never used Avastin, but in the presentation it was explained that the convection enhanced delivery of the patients who used Avastin was difficult and only reached about 1/2 of the tumor coverage that those who never had Avastin achieved. Perhaps this is a technical problem that can be solved so it helps both groups.

 


Posted on: 11/20/2020 [Click the link below for full article]

PLUS THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM RESPECT™ PHASE 1 CLINICAL TRIAL IN RECURRENT GLIOBLASTOMA

 


Click HERE to return to brain tumor news headlines.